Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Collaborator: Zhejiang Otsuka Pharmaceutical Co., Ltd.
• Treatments: Aspirin; Cilostazol

Criteria

Inclusion Criteria:

1. Age ranging from 40 to 80 years

2. After newly ischemic stroke from 3 months to 2 years

3. Brain CT or MRI shows stroke lesions and white matter lesions, ARWMC(Age Related White Matter Change)>=4

4. Moderate or mild cognitive deficits: MMSE 12-26

5. Vascular or mixed dementia: Hachinski ischemic score>4

6. Moderate or mild disability: MRS<=4,NIHSS<20

7. Informed consent

Exclusion Criteria:

1. Definitive diagnosis of dementia prior to the stroke

2. Cerebral hemorrhage in the past

3. Cerebral embolism result from cardiogenic embolus

4. Critically ills: MRS>4,NIHSS>=20

5. Bed-ridden patient who is hardly discovered newly stroke

6. patient with sever cardiac, hepatic or nephric complication

7. dementia caused not by vascular lesions

8. other diseases disturb the cognitive evaluation

9. susceptibility to varieties of allergen

10. abstain from Cilostazol or Asprin

11. antiplatelet treatment, anticoagulation or fibrinolysis are needed because of other diseases

12. rejected to participate by the patient or the family